Anti-IL17 Secukinumab in hidradenitis suppurativa: A long-term drug survival analysis.
IHS4
IL17
drug survival
hidradenitis suppurativa
secukinumab
Journal
Experimental dermatology
ISSN: 1600-0625
Titre abrégé: Exp Dermatol
Pays: Denmark
ID NLM: 9301549
Informations de publication
Date de publication:
Jul 2024
Jul 2024
Historique:
revised:
03
07
2024
received:
05
04
2024
accepted:
05
07
2024
medline:
20
7
2024
pubmed:
20
7
2024
entrez:
20
7
2024
Statut:
ppublish
Résumé
Real-world data on the long-term effectiveness of the anti-IL17 agent secukinumab in treating moderate-to-severe Hidradenitis suppurativa (HS) are lacking. In this study, 24 patients with moderate-severe HS received five weekly subcutaneous injections followed by maintenance doses every 4 weeks. Primary outcomes included HiSCR, IHS4 reduction, and DLQI measures assessed at 12-week intervals. The median secukinumab drug survival was 16.0 months (range 3-51), with a 56.5% maximal response rate at 6 months and dropout exceeding 40% at 1 year. Baseline disease burden emerged as a key predictor of treatment response, overshadowing factors like sex or BMI. Prior systemic steroid use negatively impacts drug survival. The study underscores the critical 6-month window for assessing treatment efficacy, emphasizing the importance of initial induction dosing. Additionally, the newly developed scoring system, IHS4-55, showed analogies to the older HiSCR score in capturing treatment response. In this real-life scenario, challenges persist in HS management, necessitating innovative therapeutic approaches and predictive markers.
Substances chimiques
secukinumab
DLG4EML025
Antibodies, Monoclonal, Humanized
0
Interleukin-17
0
IL17A protein, human
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e15140Informations de copyright
© 2024 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
Références
Tricarico PM, Boniotto M, Genovese G, Zouboulis CC, Marzano AV, Crovella S. An integrated approach to unravel hidradenitis suppurativa etiopathogenesis. Front Immunol. 2019;10:892. Published 2019 Apr 25. doi:10.3389/fimmu.2019.00892
Rosales Santillan M, Morss PC, Porter ML, Kimball AB. Biologic therapies for the treatment of hidradenitis suppurativa. Expert Opin Biol Ther. 2020;20(6):621‐633. doi:10.1080/14712598.2020.1732918
Roccuzzo G, Rozzo G, Burzi L, et al. Switching from adalimumab originator to biosimilars in hidradenitis suppurativa: What's beyond cost‐effectiveness? Dermatol Ther. 2022;35(11):e15803. doi:10.1111/dth.15803
Moran B, Sweeney CM, Hughes R, et al. Hidradenitis suppurativa is characterized by dysregulation of the Th17:Treg cell axis, which Is corrected by anti‐TNF therapy. J Invest Dermatol. 2017;137(11):2389‐2395. doi:10.1016/j.jid.2017.05.033
Kimball AB, Jemec GBE, Alavi A, et al. Secukinumab in moderate‐to‐severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week 16 and week 52 results of two identical, multicentre, randomised, placebo‐controlled, double‐blind phase 3 trials. Lancet. 2023;401(10378):747‐761. doi:10.1016/S0140-6736(23)000223
Repetto F, Roccuzzo G, Burzi L, et al. Drug survival of anti Interleukin‐17 and interleukin −23 agents after adalimumab failure in hidradenitis suppurativa: a pilot study. Acta Derm Venereol. 2023;103:adv5278. Published 2023 Apr 19. doi:10.2340/actadv.v103.5278
Fernandez‐Crehuet P, Haselgruber S, Padial‐Gomez A, et al. Short‐term effectiveness, safety, and potential predictors of response of Secukinumab in patients with severe hidradenitis suppurativa refractory to biologic therapy: a multicenter observational retrospective study. Dermatol Ther (Heidelb). 2023;13(4):1029‐1038. doi:10.1007/s13555-023-00906-2
Ribero S, Ramondetta A, Fabbrocini G, et al. Effectiveness of Secukinumab in the treatment of moderate‐severe hidradenitis suppurativa: results from an Italian multicentric retrospective study in a real‐life setting. J Eur Acad Dermatol Venereol. 2021;35(7):e441‐e442. doi:10.1111/jdv.17178
Ingram JR, Hadjieconomou S, Piguet V. Development of core outcome sets in hidradenitis suppurativa: systematic review of outcome measure instruments to inform the process. Br J Der‐ Matol. 2016;175(2):263‐272. doi:10.1111/bjd.14475
Tzellos T, van Straalen KR, Kyrgidis A, et al. Development and validation of IHS4‐55, an IHS4 dichotomous outcome to assess treatment effect for hidradenitis suppurativa. J Eur Acad Dermatol Venereol. 2023;37(2):395‐401. doi:10.1111/jdv.18632
Finlay AY, Khan GK. Dermatology life quality index (DLQI) – a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19:210‐216.
Van Den Reek JMPA, Kievit W, Gniadecki R, et al. Drug survival studies in dermatology: principles, purposes, and pitfalls. J Invest Dermatol. 2015;135:1‐5.
Cazzaniga S, Pezzolo E, Bettoli V, et al. Characterization of hidradenitis suppurativa phenotypes: a multidimensional latent class analysis of the National Italian Registry IRHIS. J Invest Dermatol. 2021;141(5):1236‐1242.e1. doi:10.1016/j.jid.2020.08.032
Prussick L, Rothstein B, Joshipura D, et al. Open‐label, investigator‐initiated, single‐site exploratory trial evaluating secukinumab, an anti‐interleukin‐17A monoclonal antibody, for patients with moderate‐to‐severe hidradenitis suppurativa. Br J Dermatol. 2019;181(3):609‐611. doi:10.1111/bjd.17822
Melgosa Ramos FJ, García Ruiz R, Estébanez Corrales A, MateuPuchades A. Long‐term secukinumab efficacy in patients with moderate to severe hidradenitis suppurativa: a retrospective single‐centre case series (23 patients). J Eur Acad Dermatol Venereol. 2022;37(4):e517‐e519.
Martora F, Marasca C, Cacciapuoti S, et al. Secukinumab in hidradenitis suppurativa patients who failed adalimumab: a 52‐week real‐life study. Clin Cosmet Investig Dermatol. 2024;17:159‐166. Published 2024 Jan 23. doi:10.2147/CCID.S449367
van Straalen KR, Tzellos T, Alavi A, et al. External validation of the IHS4‐55 in a European antibiotic‐treated hidradenitis suppurativa cohort. Dermatology. 2023;239(3):362‐367. doi:10.1159/000528968
Pham JP, Rosenø NAL, Roccuzzo G, et al. Drug survival of biologics in hidradenitis suppurativa: a systematic review and meta‐analysis. J Am Acad Dermatol. 2024;91:170‐172. doi:10.1016/j.jaad.2024.03.028
Avallone G, Maronese CA, Murgia G, et al. Interleukin‐17 vs. Interleukin‐23 Inhibitors in Pustular and Erythrodermic Psoriasis: A Retrospective, Multicentre Cohort Study. J Clin Med. 2023;12(4):1662. doi:10.3390/jcm12041662
Martora F, Scalvenzi M, Ruggiero A, Potestio L, Battista T, Megna M. Hidradenitis suppurativa and JAK inhibitors: a review of the published literature. Medicine (Kaunas). 2023;59(4):801. doi:10.3390/medicina59040801
Martora F, Scalvenzi M, Battista T, et al. Guselkumab, Risankizumab, and tildrakizumab in the Management of Hidradenitis Suppurativa: a review of existing trials and real‐life data. Clin Cosmet Investig Dermatol. 2023;18(16):2525‐2536. doi:10.2147/CCID.S418748
Zouboulis CC, Bechara FG, Fritz K, et al. S2k guideline for the treatment of hidradenitis suppurativa / acne inversa ‐ short version. J Dtsch Dermatol Ges. 2024;21:868‐889. doi:10.1111/ddg.15412
Maronese CA, Moltrasio C, Genovese G, Marzano AV. Biologics for hidradenitis suppurativa: evolution of the treatment paradigm. Expert Rev Clin Immunol. 2024;20(5):525‐545. doi:10.1080/1744666X.2023.2298356